Adamax peptide: what sellers claim, what Semax research shows and why none of it has been tested

Adamax is a product name, not a compound with a scientific history. Research peptide stores describe the Adamax peptide as a modified version of Semax, the seven-amino-acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed in Russia from a fragment of the hormone ACTH and registered there as a nasal drop for cognitive and cerebrovascular conditions. The modification most often stated is the addition of an adamantane group, the cage-shaped hydrocarbon found in the drugs amantadine and memantine, which vendors say protects the peptide from enzymes and helps it cross the blood-brain barrier. Some listings also describe changes to the ends of the peptide similar to those in N-acetyl Semax amidate.

We searched PubMed for the term Adamax in titles and abstracts in September 2026. Every result concerned the Adamax optimisation algorithm used in machine learning; none concerned a peptide. PubChem has no compound record under the name. There is no patent literature we could identify describing a peptide by this name, no registered clinical trial and no product information from any regulator. That leaves vendor catalogues as the only source for what Adamax is, and different vendors do not always describe the same structure, so two vials labelled Adamax from two stores may not contain the same molecule.

This distinguishes Adamax from the compounds it is sold alongside. Semax and Selank have Russian registrations and small human studies; P21 and Dihexa have animal studies from named laboratories; even PE-22-28, first described in 2017, has a peer-reviewed origin. Adamax has none of these, and a page about it is necessarily a page about Semax and about how to reason when the evidence is absent.

Because every claim for Adamax borrows from Semax, it is worth setting out what the Semax evidence actually is. In rats, tritium-labelled Semax bound specifically to membranes from the basal forebrain, and intranasal Semax at 50 and 250 µg/kg rapidly raised levels of brain-derived neurotrophic factor (BDNF), a protein involved in nerve cell survival and learning ^[1]. A single 50 µg/kg intranasal dose increased hippocampal BDNF protein about 1.4-fold and activation of its receptor TrkB about 1.6-fold, and treated rats performed better on an avoidance-learning task ^[2]. In humans, the indexed evidence is thin: a 2020 imaging study in healthy volunteers found that Semax and Selank each changed amygdala connectivity compared with placebo ^[3], and the clinical literature consists of small Russian studies, mainly in stroke, that are covered in our Semax guide and Semax vs Selank comparison.

None of that transfers automatically to a modified molecule. Peptide activity depends on exact structure, on how the chain is broken down and on which fragments survive. Adding a bulky adamantane group, or changing the ends of the chain, changes how a peptide binds its targets, how it is cleared and where it distributes. The change might improve it, worsen it or abolish activity altogether, and without a single experiment there is no way to know which. The claim that Adamax is several times more potent or longer-lasting than Semax is not a finding; it is a prediction that has never been tested.

There is a useful comparison in the literature. The developers of P21 added an adamantylated glycine to a four-amino-acid fragment of ciliary neurotrophic factor precisely to increase blood-brain barrier permeability and slow breakdown by exopeptidases ^[4]. That is the same rationale vendors give for Adamax. The difference is that the P21 group then ran the experiments: they tested the modified peptide in ageing, Alzheimer’s and Down syndrome models and published the results, and an independent group later tested it and found less than hoped. The rationale for an adamantane modification is chemically reasonable; a reasonable rationale is where research starts, not where it ends.

Vendor and affiliate pages typically claim that Adamax improves focus, memory and motivation, raises BDNF, is more dopaminergic than Semax, lasts longer, and improves physical endurance or recovery. Some claim it improves athletic endurance two to three times more than other Semax analogues. We could not find a source for any of these statements other than other vendor pages. The BDNF claim is a Semax finding in rats ^{[1] [2]}. The dopamine claim appears to derive from Russian rodent work on Semax and dopamine signalling, described in our Semax guide, which is again a Semax finding and an unusual basis for a marketing claim. The endurance claim has no source we could identify in any species.

It is also worth noting what the Semax evidence does not contain. There is no controlled trial showing Semax improves focus, memory or motivation in healthy people, and no study of Semax on endurance, muscle or recovery. So even a perfect analogue of Semax would inherit an unproven cognitive-enhancement claim and no athletic claim at all.

There are none, and there is no animal or cell study either; the total body of Adamax research is empty. Does Adamax work? Nobody has tested it. That is not a hedge; it is the complete state of the evidence. Reports of effects come from people using a product of unverified composition, without a control, and cannot distinguish the peptide from expectation.

No study has used any dose of Adamax, so there is no Adamax dosage from research to report. Vendor dosing charts, typically stated as a fixed number of micrograms per nasal spray or per injection once or twice a day, are copied from Semax charts or invented. For reference, the Semax doses with a published basis are the Russian label doses of the registered 0.1% and 1% nasal drops and the rat intranasal doses of 50 to 250 µg/kg in the BDNF studies ^{[1] [2]}; those apply to Semax, not to a modified molecule of unknown potency. The same applies to onset and duration: vendors take the duration reported for Semax by its developers and extend it for Adamax on the theory that the adamantane group slows breakdown, but no measurement of Adamax exists. Our peptide calculator and the Adamax calculator page convert vial contents into concentrations for record-keeping; they do not imply a dose.

Adamax is sold as a freeze-dried powder in vials, most often 5 mg or 10 mg, and as a pre-mixed Adamax nasal spray. PepFinder lists only vials, because a pre-mixed spray cannot be matched to a certificate of analysis for the material it was made from. Semax itself was developed as a nasal drug and the Russian labels state that 60 to 70% of a nasal dose is absorbed through the nasal lining ^[5]; whether an adamantane-modified peptide behaves the same way in the nose is unknown. There is no published human or animal study of Semax by subcutaneous injection, let alone of Adamax.

There are no safety data for Adamax in any species. The Semax product information lists mild irritation of the nasal lining with prolonged use as a side effect and advises against use in pregnancy, breastfeeding, acute psychiatric states, anxiety disorders and a history of seizures ^[5]. Whether any of that applies to Adamax is unknown, in both directions: the modified peptide could share Semax’s tolerability or could have effects of its own.

The US FDA’s compounding page states that compounded drugs containing Semax may pose a risk of immunogenicity for certain routes of administration because of the potential for aggregation and peptide-related impurities, and that the agency has limited safety information on it ^[6]. An adamantane-modified peptide is more hydrophobic than Semax and, all else being equal, more prone to aggregation, which is the property the FDA flagged. That is a theoretical concern rather than an observation, but it is the only informed thing that can be said about Adamax safety.

The practical risk is different. Because no reference standard for Adamax exists, no independent laboratory can confirm that a vial contains the molecule the vendor describes. A certificate of analysis showing a purity percentage means little when the target structure is not publicly defined and varies between sellers. Our guides to spotting a fake peptide supplier and what research peptides are explain the wider problem.

The comparison people search for has a short answer. Semax is a defined molecule with a registered product in Russia, a PubChem record, rat studies on BDNF ^{[1] [2]}, human imaging ^[3] and small clinical studies, and an FDA regulatory entry ^[6]. Adamax has a vendor description. Anyone weighing Adamax vs Semax is weighing a compound with limited evidence against one with no evidence, and the claimed advantages of Adamax, greater potency and longer action, are precisely the properties that have never been measured. N-acetyl Semax amidate, another modified Semax sold as stronger, at least has a defined structure and one laboratory study on how acetylation changes its chemistry, which is more than Adamax has.

Adamax is not an approved medicine anywhere and has no regulatory status of any kind: it does not appear on the FDA’s compounding lists, has no Russian registration, and is not named in any product information we could find. Semax, by contrast, is registered in Russia as a prescription nasal drop ^[5] and appears on the FDA’s list of compounding bulk substances that were nominated and later withdrawn, which is not an authorisation ^[6]. See our legal status overview, including the UK and US pages, for how unapproved peptides are treated in each market.

No stability data exist for Adamax. As for any freeze-dried peptide, keep it cold, dry and away from light, refrigerate reconstituted solution and use it within a limited period; see our peptide storage guide and bacteriostatic water guide.

The most useful thing a buyer can ask an Adamax vendor is what the molecule is: the full sequence and the exact position and nature of the modification. A vendor who cannot state the structure cannot have had it tested meaningfully, because an independent laboratory can only confirm identity and purity against a defined target molecule, and a purity figure for an undefined target is a number without meaning. If a structure is given, a certificate of analysis should report a measured mass consistent with it, which for an adamantane-modified Semax would be noticeably higher than Semax’s 813.9 g/mol, and an HPLC purity figure; see how to read a peptide COA and our guide to third-party peptide testing.

You can compare Adamax prices, including Adamax in the UK and Adamax in the US, alongside Semax prices, and see our list of third-party tested suppliers. A listing is not a statement that a product is legal to buy, that it contains what it claims, or that it is appropriate to use.